Prominent proteins in cancer

Prominent proteins in cancer
This is the list of significantly mutated genes (SMGs) and other proteins significantly involved in edgetic perturbations in LUSC.

Perturbation type	Gene	Citation	Cancer type	Gene-disease relation
Top gains	SPECC1(Isoform switch)	18486272	LUAD	Differentially expressed in patients with lung adenocarcinoma compared to patient group lung squamous cell carcinoma
Top gains	HECW2 (Isoform switch)	18486272	LUAD	Differentially expressed in patients with lung adenocarcinoma compared to patient group lung squamous cell carcinoma
Top specific gains	HIST1H2AB/HIST1H2AE	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top specific gains	HPDL	17082175	LUSC	Differentially expressed in tumor samples of disease-free patients (36 months after complete resection) compared to patients whose disease recurred within 18 months of complete resection.
Top specific gains	NEIL3	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top cancer-specific gains	MED12L	17082175	LUSC	Differentially expressed in tumor samples of disease-free patients (36 months after complete resection) compared to patients whose disease recurred within 18 months of complete resection.
Top losses	ACTN2	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top losses	AGTR1	29085512	LUSC	AGTR1 promoter is hypermethylated in LUSC but not in LUAD.
Top losses	APOA1	24139065	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top losses	APP	25502341	NSCLC	Depletion of amyloid precursor protein (APP) causes G0 arrest.
Top losses	BIRC7	22197230	Lung cancer	Differentially expressed in cisplatin-resistant lung cancer cells compared to parental H460 cell.
Top losses	BTNL8	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top losses	C1QTNF2	28081052	LUSC	Differentially expressed n tumor samples compared to normal samples.
Top losses	CCDC36	30333500	Lung adenocarcinoma	CCDC36 is meiotic partner of HORMAD1 that promotes homologous recombinational DNA repair and radioresistance in lung adenocarcinoma cells.
Top losses	CD1B	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top losses	CEBPE	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top losses	CMTM5	17908965	Lung cancer	CMTM5-v1 is silenced and methylated in carcinoma cell lines.
Top losses	DNASE2B	Int J Clin Exp Med 2018;11(11):11846-11854	NSCLC	DNASE2B silencing suppresses proliferation and induces cell cycle arrest in NSCLC.
Top losses	ESR2	23619141	LUSC	Polymorphism.
Top losses	FAM124B	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples
Top losses	FOXA3	30415009	Lung cancer	FOXA3 are also highly expressed in lung cancer cell lines.
Top losses	GATA1	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top losses	GDF9	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top losses	GFI1B	28667074	LUSC	T-3775440 exhibits anticancer activity in SCLC cells by disrupting the interaction between LSD1 and the SNAG domain proteins INSM1 and GFI1B.
Top losses	IL9R	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top losses	INCA1	22197230	Lung cancer	Differentially expressed in cisplatin-resistant lung cancer cells compared to parental H460 cell
Top losses	KCNA5	8394676	SCLC	The expression of Kv1.5 is remodeled in human cancer cells from the lungs.
Top losses	KHDRBS2	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top losses	L1TD1	28093071	NSCLC	L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.
Top losses	MAP1LC3C	26208877	NSCLC	Less abundant in breast cancer and non-small cell lung cancers than in matched normal tissue controls
Top losses	MYH7B	20161782	SCC; invasive	Up-regulated genes in invasive SCC associated with tissue fibrosis.
Top losses	MYOC	24563482:2019210:22281030	LUSC (potentially)	Myocilin regulates cell proliferation. MYOC interacts with olfactomedin III. Olfactomedin III expression contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line.
Top losses	NR0B2	22197230	Lung cancer	Differentially expressed in cisplatin-resistant lung cancer cells compared to parental H460 cell.
Top losses	P2RY12	22768131	NSCLC	Patients with a medium methylation level of P2RY12 had better survival than patients with high-level methylation.
Top losses	PACRG	22197230	Lung cancer	Differentially expressed in cisplatin-resistant lung cancer cells compared to parental H460 cell.
Top losses	RXRG	29866045	LUSC	Down-regulated in LUSC.
Top losses	SH3GL2	22968441	NSCLC	SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.
Top losses	TRIM55	28789440	NSCLC	Differentially expressed in NSCLC tissue.
Top losses	TRIM69	24860162	NSCLC	RNAi-mediated attenuation of TRIM69 was sufficient to inhibit tumor growth in vivo.
Top losses	TUBB1	23634282	Lung cancer	Slug increases sensitivity to tubulin-binding agents via the downregulation of betaIII and betaIVa-tubulin(TBB1) in lung cancer cells.
Top losses	USHBP1	28081052	LUSC	Down-regulated in LUSC tissue.
Top losses	USP49	31001918	NSCLC	Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
Top losses	VTN	22197230	Lung cancer	Differentially expressed in cisplatin-resistant lung cancer cells compared to parental H460 cell.
Top cancer-specific losses	CD1B	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
Top cancer-specific losses	FAM124B	16188928	LUSC	Differentially expressed in tumor samples compared to normal samples.
SMGs within edgetic gains or losses	ARID1A	24618703	LUSC	ARID1A mutations associated with LUSC.
SMGs within edgetic gains or losses	CUL3	27499952	LUSC	Polymorphism
SMGs within edgetic gains or losses	EP300	28794006	LUSC	EP300 is a mediator of SOX2-dependent squamous differentiation and LUSC growth.
SMGs within edgetic gains or losses	FAT1	28245875	LUSC	Mutation in FAT1.
SMGs within edgetic gains or losses	FBXW7	28177435	LUSC	FBXW7 and KEAP1 mutations were associated with poor response to adjuvant therapy of LUSC.
SMGs within edgetic gains or losses	FGFR2	30391781	LUSC	FGFR2 mutation associated with LUSC.
SMGs within edgetic gains or losses	KLF5	27158780	LUSC	KLF5 mutation associated with LUSC.
SMGs within edgetic gains or losses	LEPROTL1	30943467	NSCLC	LEPROTL1 mutation associated with NSCLC.
SMGs within edgetic gains or losses	NOTCH1	24743148	LUSC	Down-regulated in LUSC samples.
SMGs within edgetic gains or losses	PIK3CA	28177435	LUSC	PIK3CA mutations associated with LUSC.
SMGs within edgetic gains or losses	PTEN	24284056	LUSC	PTEN expression in LUSC samples was lower compared to lung adenoma samples.
SMGs within edgetic gains or losses	RASA1	27158780	LUSC	RASA1 mutation associated with LUSC.
SMGs within edgetic gains or losses	RB1	25684524	LUSC	Polymorphism.
SMGs within edgetic gains or losses	TP53	21623257	LUSC	Polymorphism.
SMGs within edgetic gains or losses	USP44	23187126	Lung adenoma	Mice lacking Usp44 were prone to the development of spontaneous tumors; particularly in the lungs.

To download a file, either filter the gene of interest or select all the entries and then press the "Download as Excel table" button